48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients

摘要: ![Graphic][1] Introduction Packed red blood cell transfusion is often required for the treatment of anemia in patients (pts) with myelodysplastic syndromes (MDS). Transfusion requirement associated poorer clinical outcomes and reduced overall survival (OS) MDS. We prospectively collected data on chelated non-chelated, transfused, lower-risk MDS pts. OS, leukemic transformation, events are reported these groups at 48 mos study. Methods This 5-year, non-interventional registry enrolled 599 pts from 107 US centers. Pts were ≥18 years old (WHO, FAB classification, and/or IPSS) transfusional iron overload (serum ferritin ≥1000 μg/L ≥20 packed units ≥6 every 12 weeks). The group included all who had ever used chelation; sub-analysis was performed chelation. Assessments 6 5 or until death demographics, survival, disease status, comorbidities, causes death, therapy. Results present results non-chelated those mos. Baseline demographics IPSS risk status similar between groups, although burden appeared higher ([Table 1][2]). At mos, 120 continued 479 discontinued (379 died [63.3%]; 64 lost to follow-up [10.7%]; 25 other [4.2%]; 11 completed study [1.8%]). In all, 269 (44.9%) received chelation therapy; 202 lifetime percentage therapy lower among (88.2%) vs (93.6%; P =0.0425). enrollment, cardiac vascular comorbid conditions endocrine trended (52.1% 30.7% [ 0.05 comparisons). Presence cardiovascular comorbidities a significantly shorter mean (SE) OS (89.1 [5.83] 85.2 [4.43] mos; <0.01); however this association not seen comorbidities. Median longer ( <0.0001; [Table 2][3]). Most frequent MDS/acute myeloid leukemia (AML), events, infection. Time diagnosis transformation <0.0001). View table: Table 1 Demographics, Risk Status, Burden View 2 Summary Survival AML Transformation Months Conclusions time transformation. baseline, fewer characteristics groups. Additional assessments over 5-year duration will provide further information outcomes. Disclosures: Lyons : Incyte: Consultancy, Research Funding; Amgen: Novartis Pharmaceutical: Telik: Funding. Paley: Pharmaceuticals: Employment. Esposito: McNamara: Garcia-Manero: Funding. [1]: /embed/inline-graphic-2.gif [2]: #T1 [3]: #T2